stocks logo

ADXN

Addex Therapeutics Ltd
$
8.570
+0.295(3.565%)1D
  • Overview
  • Forecast
  • Valuation
  • Earnings
Line
Line
|
Candle
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
8.570
Open
8.570
VWAP
8.57
Vol
293.00
Mkt Cap
1.58B
Low
8.570
Amount
2.51K
EV/EBITDA(TTM)
--
Total Shares
1.07M
EV
7.94M
EV/OCF(TTM)
--
P/S(TTM)
23.24
Addex Therapeutics Ltd is a Switzerland-based clinical-stage pharmaceutical company. The Company focuses on development and commercialization of orally available small molecule drugs known as allosteric modulators for neurological disorders. The Company’s clinical programs pipeline include dipraglurant (mGlu5 NAM), which is Phase 2a placebo-controlled clinical trial for Parkinson's disease levodopa-induced dyskinesia (PD-LID), and is being prepared to enter registration trials for PD-LID, and ADX71149 (mGlu2 positive allosteric modulator or PAM), which is being developed in collaboration by its partner Janssen Pharmaceuticals, Inc to treat schizophrenia and anxious depression. It also is advancing several preclinical programs, including GABABPAM for pain, overactive bladder and other disorders, mGlu7 NAM for post-traumatic stress disorder, mGlu2 NAM for mild neurocognitive disorders, mGlu4 PAM for Parkinson’s disease and mGlu3 PAM for neurodegenerative disorders.
Show More

Market Estimates

Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2024Q3
FY2024Q4
FY2025Q2
110.00K
-66.57%
--
--
150.00K
-2.25%
--
--
200.00K
+73.49%
--
--
Estimates Revision
The market is revising Upward the revenue expectations for Addex Therapeutics Ltd (ADXN) for FY2025, with the revenue forecasts being adjusted by 100% over the past three months. During the same period, the stock price has changed by 5.02%.
Revenue Estimates for FY2025
Revise Upward
up Image
+100%
In Past 3 Month
EPS Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
Stock Price
Go Up
up Image
+5.02%
In Past 3 Month

Valuation Metrics

The current forward P/E ratio for Addex Therapeutics Ltd (ADXN.O) is 0.00, compared to its 5-year average forward P/E of -1.62. For a more detailed relative valuation and DCF analysis to assess Addex Therapeutics Ltd 's fair value, click here.

Forward PE

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-1.62
Current PE
0.00
Overvalued PE
-0.40
Undervalued PE
-2.84

Forward EV/EBITDA

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-1.01
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
-0.19
Undervalued EV/EBITDA
-1.83

Forward PS

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
18.68
Current PS
4.41
Overvalued PS
41.03
Undervalued PS
-3.66

Financials

Annual
Quarterly
FY2024Q4
YoY :
+161.22%
453.71K
Total Revenue
FY2024Q4
YoY :
-38.34%
-507.79K
Operating Profit
FY2024Q4
YoY :
+33.82%
-1.36M
Net Income after Tax
FY2024Q4
YoY :
-75.00%
-0.01
EPS - Diluted
FY2024Q4
YoY :
-95.91%
-28.55K
Free Cash Flow
FY2024Q4
YoY :
0.00%
100.00
Gross Profit Margin - %
FY2024Q4
YoY :
-48.77%
-298.83
Net Margin - %

Trading Trends

Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
9.0K
Volume
1
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months

ADXN News & Events

Events Timeline

2025-06-06 (ET)
2025-06-06
05:06:10
Addex reports anti-tussive activity of GABAB positive allosteric modulator
select
2025-04-30 (ET)
2025-04-30
05:39:19
Addex Therapeutics enters collaboration with Sinntaxis AB
select
2025-04-17 (ET)
2025-04-17
05:21:07
Addex Therapeutics regains rights to ADX71149
select
Sign Up For More Events

News

8.5
06-30SeekingAlpha
Stalicla secures CHF 2M investment led by Addex for neuropsychiatric drug development
9.0
06-25Newsfilter
Addex Shareholders Approve All Resolutions at Annual General Meeting
9.5
06-19Newsfilter
Addex Therapeutics Reports Q1 2025 Financial Results and Provides Corporate Update
Sign Up For More News

FAQ

arrow icon

What is Addex Therapeutics Ltd (ADXN) stock price today?

The current price of ADXN is 8.57 USD — it has increased 3.56 % in the last trading day.

arrow icon

What is Addex Therapeutics Ltd (ADXN)'s business?

arrow icon

What is the price predicton of ADXN Stock?

arrow icon

What is Addex Therapeutics Ltd (ADXN)'s revenue for the last quarter?

arrow icon

What is Addex Therapeutics Ltd (ADXN)'s earnings per share (EPS) for the last quarter?

arrow icon

What changes have occurred in the market's expectations for Addex Therapeutics Ltd (ADXN)'s fundamentals?

arrow icon

How many employees does Addex Therapeutics Ltd (ADXN). have?

arrow icon

What is Addex Therapeutics Ltd (ADXN) market cap?